Cassava Sciences, Inc. Profile Avatar - Palmy Investing

Cassava Sciences, Inc.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational dia…

Biotechnology
US, Austin [HQ]

Risk Factors

By Management
Not Available

    No Risk Factor available yet. You can request "Risk Factors" through an email.

End of SAVA's Analysis
CIK: 1069530 CUSIP: 14817C107 ISIN: US14817C1071 LEI: - UEI: -
Secondary Listings
SAVA has no secondary listings inside our databases.